A Comparative Study of Intraocular Pressure Control Using Selective Laser Trabeculoplasty and Latanoprost as Initial Treatments for Primary Open Angle Glaucoma and Ocular Hypertension in Lagos State University Teaching Hospital

NCT07310719 | Recruiting DMC

• 1 other identifier: LagosSHSC
• Study Type: interventional
• Target: 138
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to compare the short-term efficacy and safety of selective laser trabeculoplasty (SLT) to 0.005% latanoprost eye drops in lowering intraocular pressure (IOP) as primary therapy in treatment-naïve patients diagnosed as early to moderate primary open-angle glaucoma(POAG) or ocular hypertension (OHT) in the Lagos State University Teaching Hospital, Ikeja. The main questions it aims to answer are:

1. 1.Will Selective Laser Trabeculoplasty be an equally effective treatment option compared with 0.005% Latanoprost eyedrops in reducing Intraocular Pressure when used alone as first-line therapy in Nigerian patients with POAG and OHT?
2. 2.Will Selective Laser Trabeculoplasty record a similar safety profile compared with 0.005% Latanoprost when used independently as a primary therapy?
3. 3.How will the quality of life of patients who undergo Selective Laser Trabeculoplasty treatment compare with patients on 0.005% Latanoprost eyedrops?

Conditions

Primary Open Angle Glaucoma or Ocular Hypertension

Keywords

Selective laser trabeculoplasty

Outcome Measures

Primary Outcomes (1)

• Percentage intraocular pressure reduction from baseline

  To compare the percentage reduction in IOP from baseline using SLT and 0.005% Latanoprost eye drops, each used independently as primary therapy over 3 months

  3 months

Study Arms (2)

Latanoprost 0.005%

ACTIVE COMPARATOR

Latanoprost is an ocular hypotensive prostaglandin F2-alpha isopropyl ester prodrug that lowers IOP by increasing aqueous humour outflow through the uveoscleral pathway. Evidence from experimental and clinical trials suggests that Prostaglandin analogs are first-line agents as medical therapy for glaucoma because of the higher IOP-lowering effect, lower systemic side effects, and once daily dosing compared with other classes of drugs. Participants in this group will be required to instill latanoprost in both eyes daily in the evenings.

Other: Latanoprost (0.005%)

Selective laser trabeculoplasty

EXPERIMENTAL

Selective laser trabeculoplasty is a non-invasive, laser-based treatment that targets specific cells in the trabecular meshwork (TM) to improve aqueous humor outflow, thereby reducing intraocular pressure in patients with glaucoma or ocular hypertension. The selective nature of SLT reduces collateral tissue damage, making it a more advantageous option compared to other laser treatments, as it preserves surrounding tissue while effectively targeting the trabecular meshwork

Procedure: Selective laser trabeculoplasty

Interventions

Selective laser trabeculoplasty PROCEDURE

Selective laser trabeculoplasty is a laser based treatment that reduces intraocular pressure. it is a safe alternative to medical therapy and surgery.

Selective laser trabeculoplasty

Latanoprost (0.005%) OTHER

Latanoprost is a prostaglandin analogue, a first-line ocular hypotensive medication because of it's high intraocular pressure lowering efficacy.

Latanoprost 0.005%

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients aged 18years and above.
• Patients newly diagnosed as Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
• Patients with elevated IOP greater than 21mmHg (average of 3 measurements taken on 3 different clinic visits).
• Patients categorized as early or moderate glaucoma POAG (cup -disc ratio 0.5 to 0.7, visual field analysis MD - 6dB to -12dB and disc damage likelihood score (DDLS) 5 to 7) on funduscopy, Optical coherence tomography, and fundus photograph
• Patients who agree to participate in the study after informed consent.

You may not qualify if:

• A prior medical, surgical, or laser treatment for glaucoma
• Patients diagnosed with primary congenital glaucoma or secondary glaucoma
• Advanced glaucoma (CDR greater than 0.8, visual field analysis MD more than -12dB and DDLS stage 8 and above)
• Patients with cloudy cornea or corneal opacity that would impair the view of the anterior chamber angles, fundus, or give false IOP readings
• Patients with media opacity, such as cataracts, vitreous haze, or vitreous hemorrhage that prevents examination of the posterior segment.
• Patients who have undergone previous ocular surgeries (cataract surgery, trabeculectomy).
• Patients with a history of ocular trauma or uveitis
• Pregnant and lactating women.

Sponsors & Collaborators

• Lagos State Health Service Commission: lead

Study Sites (1)

Lagos State University teaching Hospital Eye Institute

Ikeja, Lagos, Nigeria

RECRUITING

MeSH Terms

Conditions

Glaucoma, Open-Angle; Ocular Hypertension

Interventions

Latanoprost

Condition Hierarchy (Ancestors)

Glaucoma; Eye Diseases

Intervention Hierarchy (Ancestors)

Prostaglandins F, Synthetic; Prostaglandins, Synthetic; Prostaglandins; Eicosanoids; Fatty Acids, Unsaturated; Fatty Acids; Lipids; Autacoids; Inflammation Mediators; Biological Factors

Study Officials

• Prof B. Adekoya, FWACS, MD

  Lagos State University

  STUDY DIRECTOR

Central Study Contacts

Anne I. Abang-Obi, MBBS

CONTACT

+234 7061339223; iyeundiandeye@gmail.com

Chidinma C. Onyejekwe, FMCOph

CONTACT

+234 7060645714

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: December 9, 2025
• First Posted: December 30, 2025
• Study Start: October 15, 2025
• Primary Completion (Estimated): September 1, 2026
• Study Completion (Estimated): November 1, 2026
• Last Updated: December 30, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, CSR
• Time Frame: Requests for data can be submitted 9 months after article is published and data will be accessible for up to 3 years.
• Access Criteria: Access to Individual Participant Data (IPD) may be requested by researchers carrying out Independent Scientific research after a research proposal, Statistical Analysis Plan (SAP) and Data Sharing Agreement (DSA) are reviewed, approved and signed.

Locations

NG (1)